Have a look at this from the Cynata website:
https://www.cynata.com/graftversushostdisease
The statement highlighted in yellow is made from a review article from 2019 (reference 5).
Given what we NOW know about survival rates of MSCs and GVHD, you would think that Cynata would update their website as the 2019 article is old news and more recent information has come to hand by way of Mesoblast?
People reading this article aren't being given the full picture?
They probably haven't had time to update this on their webpage because they have been too busy achieving KPIs.
I've also highlighted that Cynata did update this particular page in 2022. Obviously after May 2022 when the FDA announcement for the P2 was made. But also obviously not since Mesoblast has made their announcements regarding MSCs and GVHD longer term survival, later in 2022.
Given that Cynata has only done a P1 for GVHD and the article on their website doesn't provide the complete and up-to-date picture, it makes you wonder, doesn't it.
I'm confused!
I mean why would they do this?
Maybe
@JB1975 knows why?
(20min delay)